	US 12,186,390 B2
	Vaccine delivery method
Donald A. Harn, Athens, GA (US); Rafaella Queiroz, Minas Gerais (BR); Lisa Shollenberger, Norfolk, VA (US); and Emily-Joy Farrah Samli, Athens, GA (US)
Assigned to UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US)
Filed by UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., Athens, GA (US)
Filed on Jun. 13, 2022, as Appl. No. 17/838,890.
Application 17/838,890 is a continuation of application No. 17/061,696, filed on Oct. 2, 2020, granted, now 11,524,072.
Application 17/061,696 is a continuation of application No. 15/411,083, filed on Jan. 20, 2017, abandoned.
Application 15/411,083 is a continuation of application No. 13/793,329, filed on Mar. 11, 2013, granted, now 9,566,338, issued on Feb. 14, 2017.
Application 13/793,329 is a continuation in part of application No. PCT/US2012/034012, filed on Apr. 18, 2012.
Claims priority of provisional application 61/476,431, filed on Apr. 18, 2011.
Prior Publication US 2022/0347295 A1, Nov. 3, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/39 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 39/00 (2006.01); A61K 39/012 (2006.01); A61K 39/02 (2006.01); A61K 39/04 (2006.01); A61K 39/05 (2006.01); A61K 39/08 (2006.01); A61K 39/085 (2006.01); A61K 39/09 (2006.01); A61K 39/102 (2006.01); A61K 39/104 (2006.01); A61K 39/108 (2006.01); A61K 39/112 (2006.01); A61K 39/12 (2006.01); A61K 39/145 (2006.01); A61K 39/15 (2006.01); A61K 39/155 (2006.01); A61K 39/17 (2006.01); A61K 39/215 (2006.01); A61K 39/255 (2006.01); A61K 39/265 (2006.01); A61K 39/29 (2006.01); A61K 47/42 (2017.01)

CPC A61K 39/39 (2013.01) [A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 39/00 (2013.01); A61K 39/0003 (2013.01); A61K 39/012 (2013.01); A61K 39/0208 (2013.01); A61K 39/0258 (2013.01); A61K 39/0275 (2013.01); A61K 39/04 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/085 (2013.01); A61K 39/092 (2013.01); A61K 39/099 (2013.01); A61K 39/102 (2013.01); A61K 39/104 (2013.01); A61K 39/1045 (2013.01); A61K 39/12 (2013.01); A61K 39/145 (2013.01); A61K 39/15 (2013.01); A61K 39/155 (2013.01); A61K 39/17 (2013.01); A61K 39/215 (2013.01); A61K 39/255 (2013.01); A61K 39/265 (2013.01); A61K 39/29 (2013.01); A61K 39/292 (2013.01); A61K 47/42 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/552 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55516 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55561 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/575 (2013.01); C12N 2710/16334 (2013.01); C12N 2710/16734 (2013.01); C12N 2710/24034 (2013.01); C12N 2720/10034 (2013.01); C12N 2720/12334 (2013.01); C12N 2730/10134 (2013.01); C12N 2750/10034 (2013.01); C12N 2750/14334 (2013.01); C12N 2760/16134 (2013.01); C12N 2760/16171 (2013.01); C12N 2760/18034 (2013.01); C12N 2760/18134 (2013.01); C12N 2770/10034 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/24334 (2013.01); C12N 2770/32334 (2013.01); Y02A 50/30 (2018.01)]

23 Claims

1. A vaccine composition comprising a peptide hydrogel of the peptide scaffold RADARADARADARADA (SEQ ID NO:2), an antigen, wherein the antigen is selected from a hepatitis antigen, a human immunodeficiency virus (HIV) antigen, or a tuberculosis antigen, and a TLR9 agonist, wherein the vaccine composition is a liquid at room temperature, non-physiological pH, and/or non-physiological salt concentrations and a gel at physiological pH, physiological salt concentrations and/or physiological temperatures.